JP2017101009A - 抗アカントアメーバ剤及びその製造法 - Google Patents

抗アカントアメーバ剤及びその製造法 Download PDF

Info

Publication number
JP2017101009A
JP2017101009A JP2015237951A JP2015237951A JP2017101009A JP 2017101009 A JP2017101009 A JP 2017101009A JP 2015237951 A JP2015237951 A JP 2015237951A JP 2015237951 A JP2015237951 A JP 2015237951A JP 2017101009 A JP2017101009 A JP 2017101009A
Authority
JP
Japan
Prior art keywords
plane
luliconazole
crystal
powder
acanthamoeba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015237951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017101009A5 (https=
Inventor
宮田　善之
Yoshiyuki Miyata
善之 宮田
孝明 増田
Takaaki Masuda
孝明 増田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Priority to JP2015237951A priority Critical patent/JP2017101009A/ja
Priority to KR1020160067306A priority patent/KR20170066196A/ko
Priority to CN201610388617.4A priority patent/CN106822104A/zh
Priority to US15/781,030 priority patent/US20200268716A1/en
Priority to PCT/JP2016/003106 priority patent/WO2017094204A1/en
Publication of JP2017101009A publication Critical patent/JP2017101009A/ja
Publication of JP2017101009A5 publication Critical patent/JP2017101009A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015237951A 2015-12-04 2015-12-04 抗アカントアメーバ剤及びその製造法 Pending JP2017101009A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2015237951A JP2017101009A (ja) 2015-12-04 2015-12-04 抗アカントアメーバ剤及びその製造法
KR1020160067306A KR20170066196A (ko) 2015-12-04 2016-05-31 항아칸트아메바제 및 그 제조방법
CN201610388617.4A CN106822104A (zh) 2015-12-04 2016-06-02 抗棘阿米巴属药物及其生产方法
US15/781,030 US20200268716A1 (en) 2015-12-04 2016-06-28 Luliconazole as anti-acanthamoeba agent and method for producing the same
PCT/JP2016/003106 WO2017094204A1 (en) 2015-12-04 2016-06-28 Luliconazole as anti-acanthamoeba agent and method for producing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015237951A JP2017101009A (ja) 2015-12-04 2015-12-04 抗アカントアメーバ剤及びその製造法

Publications (2)

Publication Number Publication Date
JP2017101009A true JP2017101009A (ja) 2017-06-08
JP2017101009A5 JP2017101009A5 (https=) 2019-01-24

Family

ID=56413827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015237951A Pending JP2017101009A (ja) 2015-12-04 2015-12-04 抗アカントアメーバ剤及びその製造法

Country Status (5)

Country Link
US (1) US20200268716A1 (https=)
JP (1) JP2017101009A (https=)
KR (1) KR20170066196A (https=)
CN (1) CN106822104A (https=)
WO (1) WO2017094204A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019150383A1 (en) * 2018-02-05 2019-08-08 Nalla Surya Prakash Rao A process for preparation of luliconazole
US12433872B2 (en) 2018-10-17 2025-10-07 Georgia State University Research Foundation, Inc. Treatment of Acanthamoeba or Balamuthia trophozoites and/or cysts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60218387A (ja) 1984-04-14 1985-11-01 Nippon Nohyaku Co Ltd ケテンｓ，ｓ−アセタ−ル類
JP5812465B2 (ja) 2010-04-28 2015-11-11 学校法人玉川学園 抗アカントアメーバ用組成物、アカントアメーバ角膜炎の予防及び治療剤並びにコンタクトレンズケア溶液
CN103012385B (zh) 2012-02-17 2015-07-08 山东威智医药工业有限公司 卢立康唑的晶型及其制备方法
WO2014041708A1 (en) * 2012-09-14 2014-03-20 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
WO2014042231A1 (en) 2012-09-14 2014-03-20 Pola Pharma Inc. Crystal and pharmaceutical preparation containing the same crystal
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5699234B2 (ja) 2013-06-24 2015-04-08 株式会社ポーラファルマ 結晶及び該結晶を含有してなる医薬製剤
JP5680161B1 (ja) 2013-09-06 2015-03-04 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
EP3230280A4 (en) * 2014-12-12 2018-05-09 Glenmark Pharmaceuticals Limited Process for preparation of luliconazole
JP5795693B2 (ja) 2015-01-06 2015-10-14 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物

Also Published As

Publication number Publication date
US20200268716A1 (en) 2020-08-27
WO2017094204A1 (en) 2017-06-08
KR20170066196A (ko) 2017-06-14
CN106822104A (zh) 2017-06-13

Similar Documents

Publication Publication Date Title
KR101751726B1 (ko) 특이한 정벽을 가지는 결정형 및 이 결정형을 유효 성분으로서 함유하는 약학 조성물
CN107207478B (zh) 苯并咪唑衍生物的新型结晶形式及其制备方法
JP2021504338A (ja) Ｎ−（４−（４−（シクロプロピルメチル）ピペラジン−１−カルボニル）フェニル）キノリン−８−スルホンアミドの結晶性形態
JP5589130B1 (ja) 結晶及び該結晶を含有してなる医薬製剤
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
JP7168447B2 (ja) ビラスチンの結晶形態及びそれらの調製方法
JP2017101009A (ja) 抗アカントアメーバ剤及びその製造法
US10501450B2 (en) Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
JP5698395B2 (ja) 結晶及び該結晶を含有してなる医薬製剤
US10150739B2 (en) Crystalline form of androgen receptor inhibitor and preparation method thereof
WO2013147072A1 (ja) 3-(15-ヒドロキシペンタデシル)-2,4,4-トリメチル-2-シクロヘキセン-1-オンの共結晶
JP2022533227A (ja) Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性塩形態
KR20050059132A (ko) 신규 결정
JP5951864B1 (ja) 抗ジアルジア剤
TW201908320A (zh) 一種ｂｔｋ激酶抑制劑的結晶形式及製備方法
WO2024036243A2 (en) Salts of heterocyclic inhibitors of monocarboxylate transporter 4 for the treatment of disease
WO2024062389A1 (en) Crystalline polymorph forms of a trpv1 antagonist and formulations thereof
TW201034673A (en) Novel salt of 1,3,5-triazine-2,4,6-triamine derivative

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200526